61 hedge fund portfolios held Teva Pharmaceutical Industries Limited (NYSE:TEVA) at the end of the third quarter which was 68 in the previous quarter. While we acknowledge the potential of Teva ...

As per our database, 61 hedge fund portfolios held Teva Pharmaceutical Industries Limited (NYSE:TEVA) at the end of the third quarter which was 68 in the previous quarter. While we acknowledge the ...

SOPA Images / Contributor / Getty Images Teva Pharmaceutical Industries and partner Alvotech said the Food and Drug Administration agreed to review their AVTO6 treatment for eye disorders.

JPMorgan Chase & Co. raised their price target on shares of Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a “neutral” rating in a research note on Monday, October ...

Teva Pharmaceutical Industries' Q4 2024 results ... opportunities presented in the company's pipeline. As mentioned previously, the news from Teva's pipeline has been bright, with Duvakitug ...

Shares of Teva Pharmaceutical Industries (NYSE: TEVA) were slipping Wednesday. The company's stock lost 13.5% as of 1:15 p.m. ET. The leg down comes as the S&P 500 (SNPINDEX: ^GSPC) and Nasdaq ...

Barclays analyst Balaji Prasad maintained a Buy rating on Teva Pharmaceutical (TEVA – Research Report) today and set a price target of $28.00. The company’s shares closed yesterday at $21.78.

Teva Pharmaceutical (NYSE:TEVA) shares snapped six straight sessions of losses, as the stock closed 0.88% higher at $17.21 on Wednesday. The company lost over 20% in the preceding six sessions.

Shares of NYSE TEVA opened at $17.81 on Thursday. Teva Pharmaceutical Industries has a 12 month low of $11.62 and a 12 month high of $22.80. The company has a market cap of $20.17 billion, a P/E ...

In a report released today, Chris Schott from J.P. Morgan maintained a Hold rating on Teva Pharmaceutical (TEVA – Research Report), with a price target of $21.00. The company’s shares closed ...

In February 2025, Teva Pharmaceuticals and Alvotech announced ... two additional biosimilars and new presentations of two previously partnered products. Alvotech manages development and ...

This marks the second biosimilar released in the U.S. by the strategic partnership between Teva Pharmaceuticals and ... and new presentations of two previously partnered products.